Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Defactinib · Avmapki Fakzynja Co-Pack, VS-6063

Small molecule · Inhibitor of Focal adhesion kinase (FAK) (PTK2) · developed by Verastem

Approved FDA
VSTM Developer
6 Registered trials

What is Defactinib?

Defactinib is an orally bioavailable small-molecule inhibitor of focal adhesion kinase (FAK) and Pyk2, two nonreceptor tyrosine kinases of the FAK family. It inhibits FAK autophosphorylation, which may block integrin-mediated signaling through RAS/MEK/ERK and PI3K/Akt. It is studied in ovarian cancer, lung cancer, and metastatic uveal melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Avmapki Fakzynja Co-Pack, VS-6063, 1073160-26-5, Benzamide, PF-04554878
Drug type
Small molecule
Targets
Focal adhesion kinase (FAK) (PTK2), Proline-rich tyrosine kinase 2 (Pyk2) (PTK2B) (secondary target)
Mechanism
Inhibitor of Focal adhesion kinase (FAK) (PTK2)
Pathways
RAS/MEK/ERK (MAPK), PI3K/Akt, integrin signaling, angiogenesis
Therapy area
Oncology
Developer
Verastem Inc. (VSTM)
FDA status
Approved as Avmapki Fakzynja Co-Pack, NDA219616 · FDA label
UNII
53O87HA2QU

✅ FDA-approved uses

From the indications section of the FDA label (version of May 1, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06072781 Phase 3 Low Grade Serous Ovarian Cancer Recruiting VSTM
NCT04720417 Phase 2 Metastatic Uveal Melanoma Terminated VSTM
NCT03287271 Phase 1/2 Ovarian Cancer Terminated VSTM
NCT01951690 Phase 2 Non Small Cell Lung Cancer Completed VSTM
NCT02943317 Phase 1 Epithelial Ovarian Cancer Terminated VSTM
NCT00787033 Phase 1 Cancer Completed VSTM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Low Grade Serous Ovarian CancerCancerEpithelial Ovarian CancerLung CancerMetastatic Uveal MelanomaNon Small Cell Lung CancerOvarian Cancer

Other drugs acting on PTK2

More from Verastem

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VSTM page.

Follow VSTM, the company behind Defactinib

See VSTM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VSTM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.